Press release
Diabetic Neuropathic Pain - Pipeline Insight, 2025: Innovation in Non-Opioid Therapies and Disease-Modifying Approaches Gain Momentum | DelveInsight
Diabetic neuropathic pain (DNP), a common and debilitating complication of diabetes, results from long-standing nerve damage due to chronic hyperglycemia. Characterized by burning sensations, tingling, numbness, and sharp pain, DNP severely affects patients' quality of life and functional ability. Despite several treatment options-mainly focused on symptomatic relief-there remains a considerable unmet need for safer, more effective, and disease-modifying therapies that can offer sustained benefits without central nervous system side effects or risk of addiction.As of 2025, the diabetic neuropathic pain pipeline is witnessing a wave of novel therapeutics, with over 12 drug candidates under various stages of clinical and preclinical development. These include non-opioid analgesics, sodium channel blockers (NaV1.7 and NaV1.8 inhibitors), TRP channel modulators, SIRT1 activators, and neuroprotective agents aimed at slowing or reversing nerve damage. Companies such as Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company are actively advancing novel mechanisms to target the root causes and improve long-term outcomes in DNP.
DelveInsight's report, "Diabetic Neuropathic Pain - Pipeline Insight, 2025", provides a detailed assessment of the evolving therapeutic landscape. The report offers in-depth insights into key assets in development, clinical trial progress, upcoming regulatory events, and strategic collaborations. It also highlights patient-centric innovations focused on reducing dosing frequency, minimizing systemic side effects, and enhancing treatment adherence.
With increasing R&D investment and growing awareness around diabetic complications, the pipeline is shifting from conventional symptom control toward multimodal and disease-modifying strategies. The emergence of precision medicine and biomarkers to identify patient subtypes further holds promise for tailored treatments. As these innovative candidates advance through clinical stages, the future of diabetic neuropathic pain management looks poised for a major transformation, offering renewed hope for millions suffering from this chronic condition.
Interested in learning more about the current treatment landscape and the key drivers shaping the diabetic neuropathic pain pipeline? Click here: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Key Takeaways from the Diabetic Neuropathic Pain Pipeline Report
• DelveInsight's diabetic neuropathic pain pipeline analysis depicts a strong space with 10+ active players working to develop 12+ pipeline drugs for diabetic neuropathic pain treatment.
• The leading diabetic neuropathic pain companies include Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Lateral Pharma Pty Ltd, Tris Pharma, Inc., and others are evaluating their lead assets to improve the diabetic neuropathic pain treatment landscape.
• Key diabetic neuropathic pain pipeline therapies in various stages of development include LX9211, Cemdomespib, AJH-2947, YJ001, LY3857210, LAT8881, GRT6005, and others.
• In January 2025, the FDA approved JOURNAVX, a first-in-class non-opioid analgesic targeting sodium channels, for moderate-to-severe acute pain. Vertex has received Breakthrough Therapy designation and is investigating suzetrigine for DPNP
• In December 2024, Sangamo Therapeutics announced FDA clearance of the investigational new drug (IND) application for its ST-503 program. This epigenetic therapy aims to address idiopathic small fiber neuropathy (iSFN), a chronic neuropathic pain condition that significantly impacts patients' quality of life.
• In November 2024, Sangamo Therapeutics, Inc. announced that the FDA has cleared the IND application for ST-503, an investigational epigenetic regulator aimed at treating intractable pain associated with idiopathic small fiber neuropathy (iSFN), a chronic neuropathic pain condition.
Request a sample and discover the recent breakthroughs happening in the diabetic neuropathic pain pipeline landscape at https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Neuropathic Pain Overview
Diabetic neuropathic pain is a prevalent and distressing complication of diabetes mellitus, marked by chronic pain resulting from damage to peripheral nerves. Symptoms commonly begin in the feet and gradually extend to the hands and other areas, often presenting as tingling, burning sensations, sharp or shooting pain, numbness, and increased sensitivity to touch. This discomfort tends to worsen at night, frequently disrupting sleep and significantly impairing patients' overall quality of life.
The development of diabetic neuropathic pain is driven by multiple interconnected factors. Prolonged hyperglycemia leads to nerve injury through mechanisms such as oxidative stress, inflammation, and metabolic disturbances. Compromised blood flow due to diabetic vascular complications further aggravates nerve damage. Genetic susceptibility, along with lifestyle factors like smoking and alcohol use, can also influence disease onset and severity. Diagnosis typically involves a comprehensive clinical evaluation, including a detailed patient history, neurological examination, and diagnostic tools such as nerve conduction studies and electromyography, supported by blood tests to monitor glucose control and exclude alternative neuropathies.
Find out more about diabetic neuropathic pain medication at https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Neuropathic Pain Treatment Analysis: Drug Profile
Cemdomespib: Biogen
Cemdomespib is an investigational oral small molecule and a selective C-terminal modulator of Hsp90. It is believed to exert its therapeutic effects by binding to the C-terminus of the Hsp90 protein, thereby enhancing the transcription of cytoprotective and molecular chaperone genes such as Hsp70. The upregulation of Hsp70, driven by Hsp90 modulation, is thought to provide neuroprotective benefits and alleviate diabetic nerve pain. Currently, Cemdomespib is in Phase II clinical development for the treatment of diabetic neuropathic pain.
LX9211: Lexicon Pharmaceuticals
LX9211 is an orally administered small molecule that targets adapter-associated kinase 1 (AAK1), a protein identified through Lexicon's target discovery program in collaboration with Bristol-Myers Squibb. Studies in AAK1-deficient mice have shown increased resistance to neuropathic pain, supporting the compound's therapeutic potential. LX9211 has demonstrated CNS penetration and efficacy in preclinical neuropathic pain models without engaging opioid pathways. The FDA has granted Fast Track designation to LX9211 for diabetic peripheral neuropathic pain. The drug is currently in Phase II trials for this indication.
Learn more about the novel and emerging diabetic neuropathic pain pipeline therapies at https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Diabetic Neuropathic Pain Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Diabetic Neuropathic Pain Pipeline Report
• Coverage: Global
• Key Diabetic Neuropathic Pain Companies: Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Lateral Pharma Pty Ltd, Tris Pharma, Inc., and others.
• Key Diabetic Neuropathic Pain Pipeline Therapies: LX9211, Cemdomespib, AJH-2947, YJ001, LY3857210, LAT8881, GRT6005, and others.
Dive deep into rich insights for drugs used for diabetic neuropathic pain treatment, visit: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Diabetic Neuropathic Pain Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diabetic Neuropathic Pain Pipeline Therapeutics
6. Diabetic Neuropathic Pain Pipeline: Late-Stage Products (Phase III)
7. Diabetic Neuropathic Pain Pipeline: Mid-Stage Products (Phase II)
8. Diabetic Neuropathic Pain Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetic Neuropathic Pain - Pipeline Insight, 2025: Innovation in Non-Opioid Therapies and Disease-Modifying Approaches Gain Momentum | DelveInsight here
News-ID: 4084004 • Views: …
More Releases from DelveInsight

Encephalopathy Pipeline Insight, 2025: Innovative Therapies Target Complex Pathw …
Encephalopathy refers to a broad spectrum of neurological disorders characterized by altered brain function or structure due to various causes such as metabolic imbalances, infections, toxins, trauma, and liver or kidney failure. Given its heterogeneous nature and high morbidity, encephalopathy remains a challenging condition to treat, with limited targeted therapies currently available across subtypes like hepatic, hypoxic-ischemic, uremic, and Wernicke's encephalopathy.
As of 2025, the encephalopathy treatment pipeline is expanding with…

Postpartum Depression Market to Witness Sustained Growth Through 2034, Driven by …
Postpartum depression (PPD) is a severe, mood-related disorder that affects women following childbirth, characterized by persistent sadness, emotional detachment, fatigue, and anxiety. Unlike "baby blues," which are relatively common and transient, PPD can significantly impair a mother's ability to care for her newborn and herself. With symptoms often emerging within the first few weeks post-delivery-and sometimes even during pregnancy, PPD represents a critical, yet often underdiagnosed, facet of maternal mental…

Global Patient Flow Management Solutions Market to Expand at an Impressive CAGR …
The global Patient Flow Management Solutions market is projected to grow steadily through 2032, fueled by the rising demand for streamlined hospital operations, enhanced patient experience, and improved resource utilization. As healthcare facilities face increasing patient volumes and growing complexity in care coordination, hospitals and clinics are turning to intelligent patient flow technologies to reduce bottlenecks, improve scheduling, and optimize care pathways.
Patient Flow Management Solutions include a variety of digital…

Global Electronic Health Record Market to Grow at a CAGR of 5.86% Through 2032, …
The global Electronic Health Record (EHR) market is poised for steady expansion through 2032, driven by the accelerating digitization of healthcare infrastructure, the shift toward value-based care, and growing regulatory mandates for streamlined health data management. EHR systems serve as vital digital repositories of patient health information, facilitating coordinated care, improving clinical workflows, and enhancing decision-making across healthcare settings.
The market includes a wide range of solutions-web-based, on-premise, and cloud-hosted platforms-offering…
More Releases for Diabetic
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report.
On the basis of…
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and…
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025.
To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282
Global Diabetic Socks Market: Factors Impacting the Market
The primary factors driving the growth of the global diabetic socks market are increasing…
Expanding Diabetic Populace Driven Growth For Diabetic Food Market Globally
Market Overview
Diabetic Food items are dietary items that incorporate diminished starch and sugar substance that assistance in controlling the ascent of the blood glucose. Diabetic Food additionally contains low calorie sweeteners, slim down refreshments, and so on. These items are devoured by diabetic individuals and by the general population who are not diabetic as careful step to avoid diabetes. Diabetic nourishment makers are entering into different market fragments by presenting…
Global Diabetic Footwear Market Is Driven By Growing Diabetic Patients Worldwide
Global Diabetic Footwear Market Report, published by Variant Market Research, forecast that the global market is expected to reach $9.4 Billion by 2024 from $5.3 Billion in 2016; growing at a CAGR of 7.4% from 2016 to 2024.
To browse the complete report, visit at https://www.variantmarketresearch.com/report-categories/consumer-goods/diabetic-footwear-market
Diabetic footwears are used to reduce foot amputation and ulceration risk in people suffering from diabetes. It is a lifestyle disease. Foot ulceration and debilitating…
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be…